56227-57-7

Basic information

• Product Name: (4-(2-chloroethyl)piperazin-1-yl)(phenyl)methanone
• Synonyms: (4-(2-chloroethyl)piperazin-1-yl)(phenyl)methanone
• CAS NO: 56227-57-7
• Molecular Weight: 252.744
• Mol File: 56227-57-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-(2-chloroethyl)piperazin-1-yl)(phenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(2-chloroethyl)piperazin-1-yl)(phenyl)methanone(56227-57-7)
• EPA Substance Registry System: (4-(2-chloroethyl)piperazin-1-yl)(phenyl)methanone(56227-57-7)

Safety Data

• Hazardous Substances Data: 56227-57-7(Hazardous Substances Data)

Upstream product

• 65-85-0 benzoic acid 
• 56227-56-6 (4-(2-hydroxyethyl)piperazin-1-yl)(phenyl)methanone 
• 77278-38-7 4-benzoylpiperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Design and synthesis of the 4H-chromenone derivatives against psoriasis

On basis of Quercetin moiety, two series of 20 new compounds were designed and synthesized accordingly in this study, and their anti-inflammatory activities in vitro and in vivo were evaluated. At last, compound 8A2: 3- (1- (2- (4- (5-bromo-2-chlorobenzoyl) piperazin-1-yl) ethyl)-1H-1,2,3-triazol-4-yl) methoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one with low toxicity was found the best one for inhibiting of NO. Meanwhile, this compound could significantly inhibit the expression of IL-6 (Interleukin-6), TNF-α (Tumor necrosis factor-α) and IL-17 (Interleukin-17), and also significantly down-regulate IL-17 mRNA psoriasis model in vitro. Further studies were performed to establish mouse psoriasis model induced by Imiquimod (IMQ), and the preliminary mechanism indicated that compound 8A2 may alleviate mouse psoriasis through obstructed the JAK1/2-STAT1/3 pathway. This study should be provide a basis for further study of effective treatment of psoriasis.

4, 6-DI (3,12-DIAZA-6, 9-DIAZONIADISPIRO [5.2.5.2] HEXANDECAN-1-YL) -2-METHYL-5-NITROPYRIMIDINE TETRACHLORIDE DIHYDROCHLORIDE HEXAHYDRATE FOR THE TREATMENT OF HERPETIC INFECTION AND A TOPICAL PHARMACEUTICAL COMPOSITION

?The invention relates to the use of 4, 6-di(3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate exhibiting activity against herpes virus, for the prevention and treatment of herpetic